Nazli Dizman, MD

GU Oncology Now

Nazli Dizman, MD, an Internal Medicine Resident at Yale University, discusses the combination of pembrolizumab and axitinib as a second- and further-line treatment of metastatic renal cell carcinoma. 
Dr. Dizman describes other second- and further-line treatments that are commonly administered to patients with mRCC, as well as how the design of future trials testing novel immunotherapy combinations for treating mRCC may be influenced by her recent study.View Dr. Dizman&rsquo;s comments on the <a href="https://guoncologynow.com/post/pembrolizumab-plus-axitinib-in-the-second-line-and-beyond-for-mrcc" target="_blank" rel="noopener">factors that may contribute to positive outcomes</a> for patients receiving pembrolizumab/axitinib.

Pembrolizumab Plus Axitinib and the Future of Further-line mRCC Treatments

Advanced Renal Cell Carcinoma

Dr. Dizman describes how the design of future trials testing novel immunotherapy combinations for treating mRCC may be influenced by her recent study.

Pembrolizumab/Axitinib and Future Further-line mRCC Treatments

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe